PCVX

Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.

Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026.

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.

The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%.

Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.